Atrial Fibrillation Trial, Recruiting NCT05136131 Sponsor: Ottawa Heart Institute Research Corporation Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT05136131
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults aged 18 years or older
  • People who have been diagnosed with persistent atrial fibrillation (an ongoing irregular heart rhythm condition)
  • People whose level of symptoms related to their atrial fibrillation is not yet fully known or measured

Who may not be able to join:

  • People who have a blood clot in a specific part of the heart called the left atrial appendage
  • People who have previously had a catheter-based or surgical procedure to treat their atrial fibrillation
  • People who cannot tolerate, or have medical reasons preventing them from taking, a medication called Amiodarone
  • People who have medical reasons preventing them from taking blood-thinning medication
  • People who are already taking part in another clinical trial that involves random assignment to a treatment group
  • People who are unable or unwilling to give their formal agreement to participate
  • People who have a history of not following their prescribed medical treatments
  • People who are pregnant (a pregnancy test will be required before enrolment for women who could potentially become pregnant)
  • People who are currently breastfeeding
  • People for whom the trial doctor believes participation would not be in their best interest

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Birnie, MD, Ottawa Heart Institute Research Corporation

Phone: 613-696-7000

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Ottawa Heart Institute Research Corporation
Registry
ClinicalTrials.gov
Start date
10 February 2023
Est. completion
1 May 2027

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Difference between AFEQT Scores pre and post cardioversion

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov